Regulus Therapeutics (NASDAQ:RGLS) Shares Cross Above Two Hundred Day Moving Average - Should You Sell?

Regulus Therapeutics Inc. (NASDAQ:RGLS - Get Free Report)'s stock price passed above its two hundred day moving average during trading on Monday . The stock has a two hundred day moving average of $1.47 and traded as high as $2.11. Regulus Therapeutics shares last traded at $2.01, with a volume of 542,264 shares traded.

Analyst Ratings Changes

RGLS has been the subject of a number of research reports. HC Wainwright reaffirmed a "buy" rating and set a $10.00 price target on shares of Regulus Therapeutics in a research note on Friday, March 14th. Canaccord Genuity Group reaffirmed a "buy" rating and issued a $28.00 price objective on shares of Regulus Therapeutics in a research note on Monday, March 17th. Finally, Wells Fargo & Company upgraded Regulus Therapeutics from an "equal weight" rating to an "overweight" rating and raised their price objective for the stock from $3.00 to $6.00 in a research report on Thursday, March 27th. One equities research analyst has rated the stock with a sell rating and four have issued a buy rating to the company. According to data from MarketBeat.com, Regulus Therapeutics has an average rating of "Moderate Buy" and an average target price of $12.75.

Regulus Therapeutics Stock Down 1.4 %

The company's 50-day simple moving average is $1.62 and its 200 day simple moving average is $1.50. The company has a market capitalization of $182.83 million, a P/E ratio of -2.58 and a beta of 1.03.

Regulus Therapeutics (NASDAQ:RGLS - Get Free Report) last issued its quarterly earnings data on Thursday, March 20th. The biopharmaceutical company reported ($0.20) earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of ($0.20). During the same quarter in the prior year, the firm earned ($0.40) earnings per share. As a group, equities research analysts forecast that Regulus Therapeutics Inc. will post -0.88 earnings per share for the current year.

Insider Activity

In related news, CEO Joseph P. Hagan bought 50,000 shares of the firm's stock in a transaction on Thursday, January 30th. The stock was purchased at an average price of $1.09 per share, with a total value of $54,500.00. Following the completion of the transaction, the chief executive officer now directly owns 260,808 shares of the company's stock, valued at $284,280.72. This trade represents a 23.72 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 4.35% of the stock is currently owned by insiders.

Institutional Trading of Regulus Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of the company. Jane Street Group LLC bought a new position in Regulus Therapeutics in the 3rd quarter worth $46,000. PEAK6 LLC bought a new position in shares of Regulus Therapeutics in the fourth quarter worth about $95,000. Oppenheimer & Co. Inc. acquired a new position in shares of Regulus Therapeutics during the 1st quarter worth about $96,000. Velan Capital Investment Management LP acquired a new position in shares of Regulus Therapeutics during the 4th quarter worth about $111,000. Finally, JPMorgan Chase & Co. boosted its stake in Regulus Therapeutics by 193.4% during the 3rd quarter. JPMorgan Chase & Co. now owns 78,972 shares of the biopharmaceutical company's stock valued at $124,000 after purchasing an additional 52,059 shares during the period. 92.38% of the stock is currently owned by institutional investors and hedge funds.

About Regulus Therapeutics

Regulus Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17, which is in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease.